CTMX
NASDAQ · Biotechnology
Cytomx Therapeutics Inc
$3.17
+0.07 (+2.26%)
Open$3.09
Previous Close$3.10
Day High$3.18
Day Low$3.01
52W High$8.21
52W Low$1.72
Volume—
Avg Volume2.29M
Market Cap735.84M
P/E Ratio—
EPS$-0.35
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+1,888.6% upside
Current
$3.17
$3.17
Target
$63.04
$63.04
$39.26
$63.04 avg
$88.15
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 128.23M | 113.76M | 145.29M |
| Net Income | -29,224,523 | -23,333,987 | 18.60M |
| Profit Margin | -22.8% | -21.7% | 12.8% |
| EBITDA | -35,561,533 | -29,971,128 | 25.56M |
| Free Cash Flow | — | — | 18.27M |
| Rev Growth | +12.7% | +12.7% | +5.8% |
| Debt/Equity | — | — | 0.41 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |